The open prostate cancer journal最新文献

{"title":"Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer.","authors":"T. Gilligan, W. Oh","doi":"10.1046/J.1525-1411.2001.31007-4.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.31007-4.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"25 1","pages":"45-46"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74506211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prostate Cancer Continuum: The Role of Bicalutamide (Casodex®)","authors":"G. J. C. M. Kolvenbag","doi":"10.1046/J.1525-1411.2001.003001002.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.003001002.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"55 1","pages":"2-13"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88226054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot Study of Oral Eniluracil/5-FU in the Palliation of Hormone-Refractory Prostate Cancer","authors":"M. Rosenthal, David M. Thomas, I. Davis, G. Toner, N. Noordin, J. Zalcberg","doi":"10.1046/J.1525-1411.2001.003001030.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.003001030.X","url":null,"abstract":"Objectives: Chemotherapy has an established role in the palliative therapy of patients with hormone-refractory prostate cancer (HRPC). However, optimal chemotherapy for HRPC remains poorly defined. This pilot study examined the activity and toxicity of oral 5-fluorouracil (5-FU) in combination with eniluracil for the treatment of patients with HRPC. Materials and Methods: Eighteen patients with HRPC and painful bone metastases were enrolled, although 1 patient was deemed ineligible because of incidental gastric cancer. The median age was 69 years (range, 57–82 years), median Eastern Cooperative Oncology Group performance status was 1 (range, 0–2) and median prostate specific antigen (PSA) level was 146 μg/l (range 4–2020 μg/l). Eniluracil (10 mg/m2) and 5-FU (1 mg/m2) were given orally, twice daily, for 28 days in 35-day cycles. Results: Two patients (11%) had partial pain responses (95% confidence interval, 0–29%), and 6 patients (35%) had stable pain for a minimum of 8 weeks. A reduction in analgesic use occurred in four patients (23%), and five patients (29%) experienced stable analgesic use. A partial PSA response (>50% reduction on at least two occasions, 5 weeks apart) was achieved in three patients (18%), and eight patients (48%) had stable PSA responses (PSA was rising pretreatment). Grade 4 diarrhea occurred in one patient. Grade 3 toxicities were as follows: anemia, 1 patient; lethargy, 1 patient; and deterioration in liver function, 1 patient. Conclusions: Oral eniluracil/5-FU is well tolerated in this patient population but has only modest activity. Studies in combination with other active agents may be warranted in patients with HRPC.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"35 1","pages":"30-35"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79790214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anemia Related to Hormonal Ablation Therapy for Prostate Cancer","authors":"W. Oh","doi":"10.1046/J.1525-1411.2001.003001014.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.003001014.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"43 1","pages":"14-17"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90667806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow‐up","authors":"T. Gilligan, W. Oh","doi":"10.1046/J.1525-1411.2001.003001042.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.003001042.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"60 1","pages":"42-43"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80266154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall Survival after Prostate‐Specific‐Antigen‐Detected Recurrence Following Conformal Radiation Therapy.","authors":"T. Gilligan, W. Oh","doi":"10.1046/J.1525-1411.2001.31007-2.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.31007-2.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"11 1","pages":"43-44"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73704979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Trial of the Herbal Supplement PC‐SPEC in Patients with Progressive Prostate Cancer.","authors":"T. Gilligan, W. Oh","doi":"10.1046/J.1525-1411.2001.31007-3.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.31007-3.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"112 1","pages":"44-45"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85105553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of the Role of Prostate Specific Antigen Parameters in Clinical Practice","authors":"N.N.K. Lynn, G. N. Collins, K. Alexandrou, S. Brown, P. Brooman, P. O’Reilly","doi":"10.1046/J.1525-1411.2000.24009.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24009.X","url":null,"abstract":"Introduction: Serum prostate specific antigen at the cutoff levels of 4 ng/ml has low specificity for prostate cancer. We evaluated various PSA parameters (i.e., total PSA density [tPSAD], free PSA density [fPSAD], the ratio of free to total PSA [f/t ratio], and age-specific PSA) in terms of cancer diagnosis and reducing the number of negative results for prostatic biopsies. \u0000 \u0000 \u0000 \u0000Materials and Methods: A series of 305 patients was studied. Serum tPSA and fPSA levels were measured. Prostate volume was measured with transrectal ultrasound, and sextant biopsies were performed. The f/t ratio, tPSAD, and fPSAD were calculated. Sensitivity and specificity were calculated for age-specific PSA. Receiver operating characteristic curve analysis was used to analyze the diagnostic performance of these PSA parameters. A subpopulation of patients with serum PSA levels between 4 and 10 ng/ml also was analyzed with a specific view to reducing negative results of biopsies. The Mann-Whitney U test was used to analyze the difference in these parameters between patients with benign and malignant histologies. \u0000 \u0000 \u0000 \u0000Results: There was significant difference in these PSA parameters between patients with benign and malignant histologies (p < 0.05). tPSAD had the largest area under the curve for total population as well as for patients with tPSA levels between 4 and 10 ng/ml. Although the f/t ratio had a larger area under the curve than did tPSA assay in patients with PSA levels between 4 and 10 ng/ml, the difference was not statistically significant. Using a tPSAD of 0.12 ng/ml/ml as the cutoff level of negative results of prostate biopsies could be reduced by 37% in patients with PSA levels between 4 and 10 ng/ml. Although the f/t ratio could reduce negative results of biopsies by 33.8% at the cutoff value of 0.26, 15.6% of cancers would be missed. Age-specific PSA could reduce 31% of negative prostatic biopsies, but 28% of cancers would be missed. Using combined tPSAD and the f/t ratio did not improve reductions of negative biopsy results. \u0000 \u0000 \u0000 \u0000Conclusion: tPSA density has the highest sensitivity and specificity in differentiating benign from malignant prostates. By using tPSA density, negative results of prostate biopsies can be reduced by 37%, while missing only a small number of cancers.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"10 1","pages":"205-210"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91044931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefit of Adjuvant Radiation Therapy for Localized Prostate Cancer with a Positive Surgical Margin.","authors":"G. Bubley","doi":"10.1046/J.1525-1411.2000.24005-2.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24005-2.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78611450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunohistochemical Characterization of Stromal Nodules in Benign Prostatic Hyperplasia","authors":"X. Kong, L. Zeng, Yong Yang, T. Xia, F. Gu, Y. Guo, Chung-Shuh Lee","doi":"10.1046/J.1525-1411.2000.23009.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.23009.X","url":null,"abstract":"The goal of this study is to characterize stromal nodules in benign prostatic hyperplasia (BPH) in a Chinese population. BPH specimens were obtained by superpubic enucleation. Immunohistochemical staining for vimentin, muscle actin (HHF35), and smooth muscle actin (1A4) was conducted in serial sections of 55 consecutive stromal nodules of BPH specimens. The simplest stromal nodules were undifferentiated nodules that contained vimentin-negative and smooth muscle actin-negative cells. These cells were designated as undifferentiated mesenchymal cells. Immunohistochemical staining identified two cell types. Smooth muscle cells contained smooth muscle actin and vimentin, while fibrocytes contained vimentin but not smooth muscle actin. Fibrous nodules contained fibrocytes. Two more types of stromal nodules were fibromuscular nodules, which contained mixtures of fibrocytes and smooth muscle cells, and muscular nodules, which contained only smooth muscle cells. Of 55 stromal nodules, 11 (20%) were undifferentiated, 5 (9%) were fibrous, 37 (67%) were fibromuscular, and 2 (4%) were muscular.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"22 1","pages":"199-204"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74619059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}